A Legal Battle Erupts in the Biopharma World: GSK Subsidiary TESARO Takes on AnaptysBio Over Cancer Treatment Rights
In a move that’s sure to shake up the biopharma industry, TESARO, a subsidiary of global healthcare giant GSK, has filed a lawsuit against AnaptysBio, Inc., in the Delaware Chancery Court. But here's where it gets controversial: TESARO claims AnaptysBio has materially breached their license agreement for the groundbreaking oncology treatment Jemperli (dostarlimab). This isn’t just a legal dispute—it’s a fight over the future of a drug approved in over 35 countries to treat endometrial cancer, the most common gynecologic cancer in the U.S. And this is the part most people miss: TESARO isn’t just seeking to terminate the current agreement; they want a perpetual and irrevocable license to dostarlimab, along with a 50% reduction in royalties and milestone payments to AnaptysBio. Bold move, right?
The conflict stems from AnaptysBio’s allegations that TESARO failed to meet certain obligations under the 2014 license agreement, prompting AnaptysBio to threaten revoking TESARO’s license. GSK and TESARO, however, stand firm, calling these claims entirely without merit. This clash raises a thought-provoking question: Who truly owns the rights to a drug’s future when both parties claim the other has fallen short?
Jemperli’s success is undeniable, with significant growth driven by expanded approvals in endometrial cancer across the U.S. and EU. GSK and TESARO are also pushing an ambitious clinical trial program to explore dostarlimab’s potential in treating other cancers, including rectal, colon, and head and neck cancers. The stakes are high, and the outcome of this litigation could reshape the landscape of oncology treatment partnerships.
About GSK: As a global biopharma leader, GSK is dedicated to uniting science, technology, and talent to stay ahead of disease. Learn more at gsk.com.
A Word of Caution: GSK reminds investors that forward-looking statements, including those in this announcement, are subject to risks and uncertainties. For details, refer to the “Risk Factors” section in GSK’s 2024 Annual Report on Form 20-F and its Q3 2025 Results.
What do you think? Is TESARO justified in its bold legal action, or does AnaptysBio have a legitimate claim? Let us know in the comments—this debate is far from over!
